Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Lindsey Kraft

Physician Assistant, Medical Louisville, KY Physician Assistant

NPI 1538814835 CMS profile 11412714

1169 Eastern Pkwy Ste 2265, Louisville, KY 40217

Open in the dashboard

General payments

$3,933

139 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsey Kraft of Louisville, KY is reported in the CMS Open Payments database as having received $3,933 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,132 41
2024 General $1,157 46
2023 General $1,645 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsey Kraft
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lindsey Kraft were reported at $1,132. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lindsey Kraft Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $0 $185 $55–$649 $149
2023 $1,645 $199 $58–$717 $160
2024 $1,157 $206 $62–$740 $164
2025 $1,132 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $555 15 payments
  2. Novo Nordisk Inc $410 13 payments
  3. Phathom Pharmaceuticals, Inc. $404 5 payments
  4. Pfizer Inc. $368 17 payments
  5. Amgen Inc. $326 19 payments
  6. AstraZeneca Pharmaceuticals LP $205 7 payments
  7. Astellas Pharma US Inc $180 5 payments
  8. Idorsia Pharmaceuticals US Inc $175 4 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $154 4 payments
  10. GlaxoSmithKline, LLC. $144 7 payments
  11. Other $1,011 43 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,933 139 payments
Products named General payments · program years 2023–2025
  1. VOQUEZNA $376 3 payments
  2. Otezla $308 18 payments
  3. VRAYLAR $286 4 payments
  4. NURTEC ODT $236 15 payments
  5. QULIPTA $217 8 payments
  6. UBRELVY $213 8 payments
  7. Wegovy $209 7 payments
  8. Ozempic $200 6 payments
  9. ZAVZPRET $181 7 payments
  10. QUVIVIQ $175 4 payments
  11. Other $2,205 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,030

Median for Physician Assistant: 241

Drug cost

$372,148

Median for Physician Assistant: $4,110

Branded share of claims

17.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 45 $57,238
Jardiance Empagliflozin Brand 41 $46,025
Spiriva Respimat Tiotropium Bromide Brand 43 $42,217
Trulicity Dulaglutide Brand 22 $36,704
Farxiga Dapagliflozin Propanediol Brand 19 $27,093
Mounjaro Tirzepatide Brand 19 $21,216
Linzess Linaclotide Brand 29 $18,775
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 20 $13,847
Xarelto Rivaroxaban Brand 13 $13,810
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $13,381

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $279
$279 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $57
$57 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $53
$53 21 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $50
$50 19 —
VRAYLAR
  • AbbVie, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record